Home > Insider Trading > Filing (0001140361-15-019184)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1293818	Opgen Inc	OPGN,OPGNW	Services-Medical Laboratories (8071)	061614015

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1266567	G Brian Atwood	One Sansome Street, Suite 3630 San Francisco CA 94104		Yes	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2015-05-08	413,332	$6.00	485,925	No	4	P	Indirect	See footnote
Common Stock	Acquisiton	2015-05-08	1,160,039	$0.00	1,645,964	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2015-05-08	404,725	$0.00	2,050,689	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2015-05-08	503,522	$0.00	2,554,211	No	4	C	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	C	Indirect	See footnote

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Redeemable Convertible Preferred Stock	Disposition	2015-05-08	1,160,039	$0.00	1,160,039	$0.00
Common Stock	2014 Convertible Notes	Disposition	2015-05-08	404,725	$0.00	404,725	$0.00
Common Stock	2015 Convertible Notes	Disposition	2015-05-08	503,522	$0.00	503,522	$0.00
Common Stock	Warrants	Acquisiton	2015-05-08	413,332	$0.00	413,332	$6.60

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect
0			No	4	C	Indirect
0			No	4	C	Indirect
413,332	2015-05-08	2020-05-08	No	4	P	Indirect

Footnotes

Series A Redeemable Convertible Preferred Stock automatically converted into common stock on a 1-to-1 basis upon the consummation of the Company's initial public offering.
The 2014 Convertible Notes automatically converted into shares of Series A Preferred Stock upon the consummation of the Company's initial public offering at a conversion rate of one share of Series A Preferred Stock for every $1.00 of principal converted. Each share of Series A Preferred Stock automatically converted into one share of common stock upon the consummation of the Company's initial public offering.
The 2015 Convertible Notes converted into Series A Preferred Stock upon the consummation of the Company's initial public offering at a conversion rate of 1.25 shares of Series A Preferred Stock for each $1.00 of principal converted. Each share of Series A Preferred stock automatically converted into one share of common stock upon the consummation of the Company's initial public offering.
The securities are directly held by Versant Venture Capital III, L.P. and Versant Side Fund III, L.P. (collectively, the "Versant Entities"). Mr. Atwood is a managing member of Versant Ventures III, LLC, the sole general partner of the Versant Entities and may be deemed to have shared voting and dispositive power over the shares owned by the Versant Entities. Mr. Atwood disclaims beneficial ownership of all shares held by the Versant Entities, except to the extent of his actual pecuniary interest therein.